Financial Performance - The company's revenue for Q1 2024 reached ¥1,104,366,687.97, representing a 30.60% increase compared to ¥845,614,829.78 in the same period last year[5] - Net profit attributable to shareholders was ¥47,772,301.04, a 62.03% increase from ¥29,483,336.47 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥45,535,964.51, up 60.39% from ¥28,390,423.83 in the previous year[5] - Basic earnings per share increased by 45.79% to ¥0.1194, compared to ¥0.0819 in the previous year[5] - Total operating revenue for Q1 2024 reached ¥1,104,366,687.97, an increase of 30.6% compared to ¥845,614,829.78 in Q1 2023[22] - Net profit for Q1 2024 was ¥52,500,362.09, representing a 79.9% increase from ¥29,158,078.38 in Q1 2023[23] - The total comprehensive income for the first quarter of 2024 was CNY 52,500,362.09, compared to CNY 29,158,078.38 in the same period last year, representing an increase of approximately 80%[24] - The net profit attributable to the parent company was CNY 47,772,301.04, up from CNY 29,483,336.47, indicating a growth of about 62% year-over-year[24] - Basic and diluted earnings per share increased to CNY 0.1194 from CNY 0.0819, reflecting a rise of approximately 46%[24] Cash Flow and Assets - The company's cash flow from operating activities decreased by 23.24% to ¥157,539,855.26, down from ¥205,224,849.16 in the same period last year[5] - Cash inflow from operating activities totaled CNY 1,179,478,501.35, compared to CNY 966,968,925.08 in the previous year, marking an increase of around 22%[25] - The net cash flow from operating activities decreased to CNY 157,539,855.26 from CNY 205,224,849.16, a decline of about 23%[25] - Cash inflow from investment activities was CNY 341,497,267.64, up from CNY 213,805,301.99, representing an increase of approximately 60%[27] - The net cash flow from investment activities was negative at CNY -130,842,270.82, slightly improved from CNY -134,666,915.68 year-over-year[27] - Cash inflow from financing activities was CNY 89,887,512.78, significantly lower than CNY 941,627,869.72 in the previous year, indicating a decrease of about 90%[27] - The ending cash and cash equivalents balance was CNY 572,496,711.00, down from CNY 974,774,620.88, a decrease of approximately 41%[27] - Cash and cash equivalents at the end of Q1 2024 were CNY 1,266,605,691.51, down from CNY 1,336,326,502.97 at the beginning of the period[18] - As of March 31, 2024, the company's total current assets amounted to CNY 2,963,808,764.97, an increase from CNY 2,826,254,957.65 at the beginning of the period[18] Liabilities and Shareholder Information - The total liabilities rose to ¥2,902,583,139.32, compared to ¥2,635,167,802.36, marking an increase of 10.1%[20] - The company reported a significant increase in accounts payable, which rose by 103.45% to ¥514,489,948.82, attributed to growth in sales and procurement[9] - The company reported a significant increase in accounts payable, which rose to ¥514,489,948.82 from ¥252,887,190.77, an increase of 103.5%[20] - Total number of common shareholders at the end of the reporting period is 17,684[11] - Major shareholder He Jiale holds 50.12% of shares, totaling 200,493,326 shares, with 50,500,000 shares pledged[11] - Alibaba Health Technology (China) Co., Ltd. holds 7.51% of shares, totaling 30,049,373 shares[11] - The top 10 shareholders account for significant ownership, with He Jiale and He Jialun being related parties[12] - The company has a total of 200,493,326 restricted shares held by He Jiale, with a release date set for March 1, 2026[14] - 30,049,373 shares held by Alibaba Health Technology have been released from restrictions as of March 1, 2024[14] - The company has no preferred shareholders or changes in restricted shares reported[13] - The company has not engaged in any financing or securities lending activities among the top shareholders[12] - The total number of shares held by the top 10 unrestricted shareholders includes significant stakes from various investment partnerships[11] - The company maintains a diverse shareholder base with various investment entities involved[12] Research and Development - The company's R&D expenses surged by 205.62% to ¥6,196,651.12, reflecting increased investment in drug development and information technology[9] - Research and development expenses for Q1 2024 were ¥6,196,651.12, significantly higher than ¥2,027,569.40 in Q1 2023, indicating a focus on innovation[22] Acquisitions and Market Expansion - The company signed an agreement to acquire 10% equity in Chizhou Baicaotang Pharmacy in January 2024[17] - In February 2024, the company signed an agreement to acquire 100% equity in Wuwei Guosheng Pharmacy, which will be included in the consolidated financial statements from March 2024[17] - The company signed an agreement in March 2024 to acquire 80% equity in Liu'an Ping'an Pharmacy, which will be included in the consolidated financial statements from April 2024[17] - The company has plans for market expansion through acquisitions and partnerships in the pharmacy sector[17] Audit and Reporting - The company's financial report for Q1 2024 was approved by the board on March 27, 2024[17] - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[28]
华人健康(301408) - 2024 Q1 - 季度财报